Cardio Diagnostics Holdings Inc. (CDIO) Tackling Heart Disease Through AI and Biomarker Insights

MindBio Therapeutics Corp. (MBQIF) Deploying AI for Non-Invasive Intoxication Detection

House Hearing Puts Hospital CEOs on the Spot Over Exorbitant Charges

Study Finds Exercise, Ibuprofen Combat Brain Fog in Cancer Patients

Study Uncovers Why the Risk of Breast Cancer Increases with Age

BioMedWire Spotlight Company

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

NRx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

BioMedWire Spotlight Company

Calidi Biotherapeutics Inc. (NYSE American: CLDI)

Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads.

BioMedWire Spotlight Company

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)

Tonix Pharmaceuticals Holding Corp. is a fully-integrated biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics aimed at treating and preventing human diseases and alleviating suffering. The company's development portfolio is primarily focused on central nervous system (CNS) disorders, with its lead product candidate, TNX-102 SL, showing significant promise for the management of fibromyalgia. With two successful Phase 3 studies completed, Tonix is preparing to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL, which has also been granted Fast Track designation. In addition to fibromyalgia, TNX-102 SL is being developed to treat acute stress reactions, further broadening its therapeutic potential.

BioMedWire Spotlight Company

Annovis Bio Inc. (NYSE: ANVS)

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

BioMedWire Spotlight Company

HeartBeam Inc. (NASDAQ: BEAT)

HeartBeam Inc. is a medical technology company pioneering a new approach to cardiac care by delivering clinical-grade electrocardiogram (ECG) insights outside traditional clinical settings. Its proprietary platform supports a scalable app-based solution for rhythm monitoring.

BioMedWire Spotlight Company

Aditxt Inc. (NASDAQ: ADTX)

Aditxt Inc. is a innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

BioMedWire Spotlight Company

Helus Pharma Inc. (NASDAQ: HELP) (NEO: HELP)

Helus Pharma Inc., originally founded as Cybin Inc. in 2019, is a clinical-stage pharmaceutical company developing novel serotonergic agonists (“NSAs”) for the treatment of mental health disorders.

BioMedWire Spotlight Company

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

BioMedWire Client Partners

Official NewsWire Relationships

BIO Informa

DGE Dynamic Global Events

DTC Healthcare Conference

Kiasco Reasearch

Nexus Conferences

Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

BioMedWire

1108 Lavaca St
Suite 110-BMW
Austin, TX 78701
(512) 354-7000

Company Search

Get Quote

Site Search

Copyright © . BioMedWire / 1108 Lavaca St Suite 110-BMW Austin, TX 78701 (512) 354-7000 / Disclaimers